Atrial fibrillation (AF) burden, defined as the duration of AF episodes, is a critical factor in predicting outcomes and guiding therapy. This review highlights that lower AF burden is associated with reduced stroke and heart failure risk, especially in patients with device-detected AF. Early rhythm control and AF ablation can significantly reduce cardiovascular events, particularly in those with heart failure. Technological advancements allow for accurate AF burden estimation, offering new therapeutic targets. While evidence is limited, current data suggest that reducing AF burden could be a key therapeutic goal alongside anticoagulation and cardiovascular treatment. AF burden is influenced by comorbidities and interacts with stroke risk, with higher burdens linked to greater risks. Rhythm control therapy, including AF ablation, effectively reduces AF burden and improves outcomes. The concept of AF burden is increasingly recognized in clinical guidelines, emphasizing its role in risk prediction and treatment decisions. Future research aims to define the AF burden that constitutes a significant stroke or heart failure risk, and to validate technologies for precise measurement. The integration of AF burden into clinical practice has the potential to enhance risk prediction and guide more personalized therapies. Ongoing trials are evaluating the impact of AF burden reduction on outcomes, particularly in patients with heart failure and high comorbidity. The review underscores the importance of AF burden in clinical decision-making and highlights the need for further research to refine its role in AF management.Atrial fibrillation (AF) burden, defined as the duration of AF episodes, is a critical factor in predicting outcomes and guiding therapy. This review highlights that lower AF burden is associated with reduced stroke and heart failure risk, especially in patients with device-detected AF. Early rhythm control and AF ablation can significantly reduce cardiovascular events, particularly in those with heart failure. Technological advancements allow for accurate AF burden estimation, offering new therapeutic targets. While evidence is limited, current data suggest that reducing AF burden could be a key therapeutic goal alongside anticoagulation and cardiovascular treatment. AF burden is influenced by comorbidities and interacts with stroke risk, with higher burdens linked to greater risks. Rhythm control therapy, including AF ablation, effectively reduces AF burden and improves outcomes. The concept of AF burden is increasingly recognized in clinical guidelines, emphasizing its role in risk prediction and treatment decisions. Future research aims to define the AF burden that constitutes a significant stroke or heart failure risk, and to validate technologies for precise measurement. The integration of AF burden into clinical practice has the potential to enhance risk prediction and guide more personalized therapies. Ongoing trials are evaluating the impact of AF burden reduction on outcomes, particularly in patients with heart failure and high comorbidity. The review underscores the importance of AF burden in clinical decision-making and highlights the need for further research to refine its role in AF management.